Bemiparin

Summary

Bemiparin (CHEMBL3707365) is a phase-3 clinical-stage oligosaccharide (ATC B01AB12); indicated across 7 conditions including thrombotic disease and cirrhosis of liver.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• ATC class: B01AB12
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707365
Name	Bemiparin
Type	Oligosaccharide
Max phase	3
ATC	B01AB12

Also known as: Bemiparin, BEMIPARIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	HP:0004419
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
diabetic peripheral angiopathy	2	MONDO:0000960	EFO:1000896
kidney failure	1	MONDO:0001106	HP:0000083

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE3	4
Not specified	4
PHASE2	3
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00219973	PHASE3	COMPLETED	CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
NCT00311896	PHASE3	TERMINATED	Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
NCT00448903	PHASE3	COMPLETED	Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers
NCT02802605	PHASE3	UNKNOWN	Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients
NCT00324558	PHASE2	TERMINATED	Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
NCT00369096	PHASE2	COMPLETED	Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)
NCT04420299	PHASE2	TERMINATED	Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19
NCT00413088	PHASE1	COMPLETED	Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
NCT00863577	PHASE1	COMPLETED	Pharmacokinetic Study of Two Oral Bemiparin Formulations
NCT03601338	EARLY_PHASE1	COMPLETED	Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths
NCT05569681	Not specified	RECRUITING	Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
NCT01588171	Not specified	COMPLETED	Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
NCT01630148	Not specified	COMPLETED	Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries
NCT02795065	Not specified	COMPLETED	Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).